MDR-TB patient Rohatay Abdullaeva at her home with a grandson Atabek and daughter Nadira, town of Hojeily, Karakalpakstan (Uzbekistan). Photograph by Natalia Sergeeva Photograph by Natalia Sergeeva
Report |

DR-TB Drugs Under the Microscope, 2nd Edition

English (ENG) and Spanish (ES) versions available to download

Photograph by Natalia Sergeeva

This report focuses on just some of the many factors that hamper the scaling up of DR-TB treatment – the limited availability and high cost of quality-assured medicines for resistant strains of the disease, owing to an insecure market and insufficient demand; and the research questions that remain unsolved with existing medicines.

Also, as the R&D pipeline prepares to deliver the first new compounds for TB in close to half a century, the report provides an initial assessment of the approaches to be taken in order to radically transform our ability to respond to this plague.

Additional publications in the DR-TB Drugs Under the Microscope report series are available here.

Learn more about MSF’s work to improve access to lifesaving TB treatment.

DR-TB Drugs Under the Microscope, 2nd Edition